Related Experiment Video
Updated: Mar 20, 2026

Yeast As a Chassis for Developing Functional Assays to Study Human P53
Published on: August 4, 2019
Reactivation of mutant p53 by a dietary-related compound phenethyl isothiocyanate inhibits tumor growth
M Aggarwal1, R Saxena2, E Sinclair1
1Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20007, USA.
Abstract:
Mutations in the p53 tumor-suppressor gene are prevalent in human cancers. The majority of p53 mutations are missense, which can be classified into contact mutations (that directly disrupts the DNA-binding activity of p53) and structural mutations (that disrupts the conformation of p53). Both of the mutations can disable the normal wild-type (WT) p53 activities. Nevertheless, it has been amply documented that small molecules can rescue activity from mutant p53 by restoring WT tumor-suppressive functions. These compounds hold promise for cancer therapy and have now entered clinical trials. In this study, we show that cruciferous-vegetable-derived phenethyl isothiocyanate (PEITC) can reactivate p53 mutant under in vitro and in vivo conditions, revealing a new mechanism of action for a dietary-related compound. PEITC exhibits growth-inhibitory activity in cells expressing p53 mutants with preferential activity toward p53(R175), one of the most frequent 'hotspot' mutations within the p53 sequence. Mechanistic studies revealed that PEITC induces apoptosis in a p53(R175) mutant-dependent manner by restoring p53 WT conformation and transactivation functions. Accordingly, in PEITC-treated cells the reactivated p53(R175) mutant induces apoptosis by activating canonical WT p53 targets, inducing a delay in S and G2/M phase, and by phosphorylating ATM/CHK2. Interestingly, the growth-inhibitory effects of PEITC depend on the redox state of the cell. Further, PEITC treatments render the p53(R175) mutant sensitive to degradation by the proteasome and autophagy in a concentration-dependent manner. PEITC-induced reactivation of p53(R175) and its subsequent sensitivity to the degradation pathways likely contribute to its anticancer activities. We further show that dietary supplementation of PEITC is able to reactivate WT activity in vivo as well, inhibiting tumor growth in xenograft mouse model. These findings provide the first example of mutant p53 reactivation by a dietary compound and have important implications for cancer prevention and therapy.
Insights
Phenethyl isothiocyanate (PEITC), a compound from cruciferous vegetables, reactivates mutant p53 (a tumor suppressor) in cancer cells. This dietary compound shows promise for cancer therapy by restoring normal p53 function and inhibiting tumor growth.
Area of Science:
- Molecular Biology
- Cancer Research
- Nutritional Biochemistry
Background:
- Mutations in the p53 tumor-suppressor gene are common in human cancers, leading to loss of its tumor-suppressive functions.
- Missense mutations, including contact and structural types, disable wild-type (WT) p53 activities.
- Small molecules capable of restoring WT p53 function offer potential cancer therapeutic strategies.
Purpose of the Study:
- To investigate the potential of phenethyl isothiocyanate (PEITC), a dietary compound, to reactivate mutant p53.
- To explore the anticancer mechanisms of PEITC, particularly its effects on p53(R175) mutants.
Main Methods:
- In vitro and in vivo assays to assess PEITC's effect on p53 mutant reactivation and cancer cell growth.
- Mechanistic studies involving apoptosis induction, cell cycle analysis, and target gene activation.
- Evaluation of PEITC's impact on proteasomal and autophagic degradation pathways.
- In vivo tumor growth inhibition in a xenograft mouse model.
Main Results:
- PEITC reactivated p53 mutant, including the common p53(R175) hotspot mutation, restoring WT p53 conformation and transactivation functions.
- PEITC induced p53-dependent apoptosis, cell cycle delay, and ATM/CHK2 phosphorylation.
- PEITC's anticancer effects were dependent on the cellular redox state and enhanced degradation of the reactivated p53 mutant.
- Dietary PEITC supplementation inhibited tumor growth in vivo.
Conclusions:
- PEITC reactivates mutant p53, demonstrating a novel mechanism for a dietary compound.
- PEITC exhibits anticancer activity by restoring p53 tumor-suppressive functions and promoting mutant p53 degradation.
- These findings suggest PEITC's potential for cancer prevention and therapy.
More Related Videos
04:56Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence
Published on: December 30, 2025
09:32Procedure and Key Optimization Strategies for an Automated Capillary Electrophoretic-based Immunoassay Method
Published on: September 10, 2017
Related Concept Videos
Abnormal Proliferation
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Inhibition of Cdk Activity
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
DNA Damage can Stall the Cell Cycle
DNA Damage Can Stall the Cell Cycle